Novartis to Acquire SNV4818 for $2bn Upfront and $1bn Milestones, Boosting Breast Cancer Pipeline
Novartis will pay $2bn upfront and up to $1bn in milestones to buy SNV4818, a pan-mutant selective PI3Kα inhibitor, from Synnovation’s Pikavation. The oral agent in Phase I/II trials for HR+/HER2– breast cancer and other solid tumours strengthens Novartis’ CDK inhibitor and endocrine therapy combinations, with closing due H1 2026.
1. Deal Terms and Financials
Novartis has signed an agreement to acquire Synnovation’s wholly owned subsidiary Pikavation Therapeutics, securing SNV4818 for $2bn upfront plus up to $1bn in development and regulatory milestones. The transaction covers SNV4818 and related programmes, with finalisation expected in the first half of 2026 subject to customary closing conditions and regulatory approvals.
2. SNV4818 Clinical Profile
SNV4818 is an oral, pan-mutant selective PI3Kα inhibitor currently in a Phase I/II trial for HR+/HER2– breast cancer and other advanced solid tumours. Preclinical studies have shown potent activity against common PIK3CA mutations, and the programme is positioned for potential combination with existing cyclin-dependent kinase inhibitors and endocrine therapies.
3. Strategic Implications and Timeline
The acquisition aligns with Novartis’ strategy to expand its oncology portfolio, particularly in hormone receptor-positive breast cancer, by adding precision medicine approaches targeting mutant PI3Kα. Integrating SNV4818 could enhance tolerability and durability of response when paired with current regimens, with the deal slated to close in H1 2026 once approvals are secured.